Synthetic biology is a field of biological science that involve engineering principles to redesign organisms to give them new abilities. It is possible to think of synthetic biology as the culmination or the prescriptive, deliberate stage of biology. The main product types of synthetic biology are oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organisms. Oligonucleotides are small single-stranded DNA segments that, when internalized by the cell, can specifically suppress the expression of a single protein. The various technologies include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering that are applied in pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others. The synthetic biology market research report is one of a series of new reports from The Business Research Company that provides synthetic biology market statistics, including synthetic biology industry global market size, regional shares, competitors with a synthetic biology market share, detailed synthetic biology market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic biology industry. This synthetic biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global synthetic biology market will grow from $13.11 billion in 2022 to $17.07 billion in 2023 at a compound annual growth rate (CAGR) of 30.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global synthetic biology market is expected to grow to $39.12 billion in 2027 at a CAGR of 23.0%. DNA sequencing is important in the development of the synthetic biology in many ways. DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes. These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the Human Genome Research Institute, in 2021,, costs per genome sequenced have decreased from $3 billion to approximately $300 million over the past 17 years and are projected to be gradually lowered by 10 times over the next five years. The bio-safety risks involved in synthetic biology restrains the synthetic biology market. Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, and allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information. With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market. The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California-based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc., a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. Major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I. Du Pont De Nemours and Company, Koninklijke DSM N.V., Codexis, Merck KGaA, Danaher Corporation, EnBiotix, Evonetix, Prokarium, Eurofins Scientific, Origene technologies, Pareto Biotechnologies, Blue heron, Syntrox, ATUM, and DNA2.0. North America was the largest region in the synthetic biology market in 2022. Western Europe was the second largest region in the global synthetic biology market. The regions covered in the global synthetic biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The synthetic biology market includes revenue earned by synthetic compound, technology and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global synthetic biology market is segmented - 1) By Technology: Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering 2) By Application: Pharmaceuticals And Diagnostics, Chemicals, Biofuels, Bioplastics, Other Applications 3) By Product Type: Oligonucleotides, Enzymes, Cloning and Assembly Kits, Xeno-nucleic Acids (XNA), Chassis Organism

Airway management devices are medical techniques and tools for preserving or reestablishing a secure, reliable channel for ventilation and oxygenation. Airway management devices are used to prevent and relieve airway obstruction to ensure the proper exchange of air between the patient’s lungs and atmosphere. The main types of airway management devices are infraglottic airway management devices, supraglottic airway management devices, resuscitators, laryngoscopes, and other devices. The infraglottic airway management devices are used to prevent and relieve airway obstruction to ensure the proper exchange of air between the patient’s lungs and atmosphere. These are used for applications such as anesthesia, emergency medicine, others that are used by hospitals and homecare. The airway management devices market research report is one of a series of new reports from The Business Research Company that provides airway management devices market statistics, including airway management devices industry global market size, regional shares, competitors with a airway management devices market share, detailed airway management devices market segments, market trends and opportunities, and any further data you may need to thrive in the airway management devices industry. This airway management devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global airway management devices market grew from $2.36 billion in 2022 to $2.49 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The airway management devices market is expected to grow from $2.98 billion in 2027 at a CAGR of 4.6%. The increasing prevalence of respiratory diseases is expected to propel the demand for airway management devices market over the forecast period. Airway management devices are used for difficult emergency airway management during medical procedures. According to the American Lung Association, in 2020, 148,512 people died from COPDs in the US making it sixth overall leading cause of death and fifth disease-related cause of death. Lung cancer was the deadliest cancer with 1.76 million deaths annually across the world. Moreover, 10 million people develop tuberculosis and 334 million people suffer from asthma every year. This scenario drives the growth of the airway management devices market. The complications and failures associated with airway management devices limit the growth of airway management devices. According to BioMed Research International Journal, the concerns or complications related to the supraglottic and other airway management devices include compression of vascular structures, regurgitation, aspiration of gastric contents, trauma, and nerve injury. Therefore, higher incidences of complications associated with the airway management devices question the use of devices in the first place and likely harm the market growth. The launch of innovative airway management devices is shaping the airway management devices market. For instance, in December 2021, McMurray Enhanced Airwar (MEA) was named as 2021 EMS world innovation awards winner. The MEA is specially designed to quickly open a patient’s airway facilitating ventilation and oxygenation. Similarly, in June 2020, Docsinnovent Ltd launched an advanced version of V-gel, which is a supraglottic airway device for cats and rabbits. Major players in the airway management devices market are Medtronic, Smiths Medical (A Division of Smiths Group PLC), Teleflex, Ambu, Karl Storz, Flexicare, Intersurgical, Carefusion, Mercury Medical, and Well Lead Medical Co Ltd. North America was the largest region in the airway management devices market in 2022. Western Europe was the second largest region in the global airway management devices market report.The regions covered in the global airway management devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the airway management devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The airway management devices market consists of sales of oropharyngeal airway (OPA), nasopharyngeal airway (NPA), and endotracheal airway (ETA). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global airway management devices market is segmented - 1) By Type: Infraglottic Airway Management Devices, Supraglottic Airway Management Devices, Resuscitators, Laryngoscopes, Other Devices 2) By End Use: Hospital, Homecare 3) By Application: Anesthesia, Emergency Medicine, Other Applications

Respiratory devices and equipment (therapeutic and diagnostic) are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life. Patients with respiratory disorders such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome require respiratory devices. The main types of respiratory devices and equipment are diagnostic devices, therapeutic devices, and monitoring devices. The diagnostic devices are used to diagnose respiratory-related issues. The various therapeutic devices are humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, and others. The diagnostic devices involved are spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers. These provide applications in chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea (OSA), respiratory distress syndrome (RDS), cystic fibrosis, and pneumonia. These are used by hospitals, clinics, home care settings, and ambulatory service centres. The respiratory devices and equipment (therapeutic and diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (therapeutic and diagnostic) market statistics, including respiratory devices and equipment (therapeutic and diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (therapeutic and diagnostic) market share, detailed respiratory devices and equipment (therapeutic and diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (therapeutic and diagnostic) industry. This respiratory devices and equipment (therapeutic and diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global respiratory devices and equipment (therapeutic and diagnostic) market size will grow from $29.09 billion in 2022 to $32.76 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The respiratory devices and equipment (therapeutic and diagnostic) market size is expected to grow to $50.54 billion in 2027 at a CAGR of 11.5%. The global therapeutic respiratory devices and equipment market will be driven by the increase in diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer. Growth in the geriatric population, tobacco consumption, allergens, and air pollutants increase the prevalence of respiratory diseases, in turn driving the global therapeutic respiratory devices market. According to World Health Organisation,4.9 million people die due to tobacco consumption, and smoking causes chronic obstructive pulmonary diseases (1 million deaths annually), cardiovascular and respiratory diseases (1.7 million deaths annually), and lung cancer (0.85 million deaths annually). According to an Italian journal, COPD in the U.S. is estimated to be 10% in the population aged 75 years or over. According to Asthma UK, 5.4 million people in the UK are currently receiving treatment for asthma out of these 1.1 million are children and 4.3 million are adults. A longer duration of time taken in the approval process of the respiratory devices is restricting the respiratory devices and equipment market growth. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to development costs to be borne by device manufacturers, thus acting as a restraint hindering the market growth. For instance, FDA reviews about 4,000 submissions every year and takes about 3 to 6 months in clearing most of them. In addition to this, to reduce incidences associated with the respiratory devices and ensure that the devices are safe and have the least adverse reactions, the Medicines and Healthcare products Regulatory Agency (MRHA), UK regulates and monitors the devices by restricting devices for use and sending field safety notice to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory devices and equipment market. Companies in the respiratory devices and equipment market are increasingly investing in enhanced mechanical ventilators for efficient patient management. These mechanical ventilators use artificial intelligence to improve patient management by examining, analyzing, integrating, and incorporating data from extensive sources. These AI-enabled devices ensure consistency even in the absence of expert personnel, improve patients' treatment, limit clinical mistakes, and predict prolonged mechanical ventilation by using artificial intelligence techniques. Some of the major companies offering intelligent mechanical ventilators such as Hamilton Medical AG, Koninklijke Philips N.V., and others. In June 2021, Philips respironics issued a voluntary recall notification after discovering potential health risks related to CPAP, BiPAP and Mechanical ventilator devices. The notification also included a field safety notice for users who did not intend to send the devices for repair. Major players in the respiratory devices and equipment market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, Dragerwerk AG, Medtronic PLC., Masimo corp., and CareFusion Corporation. Asia-Pacific was the largest region in respiratory devices and equipment (therapeutic and diagnostic) market in 2022. Western Europe was the second-largest region in respiratory devices and equipment (therapeutic and diagnostic) market. The regions covered in respiratory devices and equipment (therapeutic and diagnostic) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The respiratory devices and equipment (therapeutic and diagnostic) market consists of sales of instruments such as humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, spirometer, polysomnographs, peak flow meters, pulse oximeters, capnographs, and gas analyzers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global respiratory devices and equipment (therapeutic and diagnostic) market is segmented - 1) By Type: Diagnostic devices, Therapeutic devices, Monitoring devices 2)By End User: Hospitals, Clinics, Homecare settings, Ambulatory service centers, 3) By Therapeutic Devices: Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Other Therapeutic Devices 4) By Diagnostic Devices: Spirometer, Polysomnographs, Peak Flow Meters 5) By Monitoring Devices: Pulse oximeters, Capnographs, Gas analyzers 6) By Application: Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distress Syndrome (RDS), Cystic Fibrosis, Pneumonia

Nasal splints are devices designed to fit inside or on the nose to provide support after nasal surgery. Nasal splints include intranasal splints and external nasal splints. Intranasal splints are placed into the nose and are used to maintain septal stability and prevent intranasal adhesions following septal surgery. External nasal splints are placed on the outer part of the nose and used to prevent the nose from moving following rhinoplasty or nasal contouring procedures. The main types of nasal splints market are malleable nasal splints, airway nasal splints, and bivalve nasal splints. The bivalve nasal splints are designed to provide septal support and reduce or prevent adhesions between the septum and lateral nasal wall following surgery. The various applications involved are plastic surgery, rhinological operations, ENT surgery, and others. The various end-users are hospitals and clinics, home care, research centres, and others. The nasal splints market research report is one of a series of new reports from The Business Research Company that provides nasal splints market statistics, including nasal splints industry global market size, regional shares, competitors with a nasal splints market share, detailed nasal splints market segments, market trends and opportunities, and any further data you may need to thrive in the nasal splints industry. This nasal splints market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nasal splints market size will grow from $6.25 billion in 2022 to $6.9 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nasal splints market size is expected to grow to $9.68 billion in 2027 at a CAGR of 8.8%. Rhinoplasty is one of the most commonly performed reconstructive cosmetic surgery across the globe and Rhinoplasty accounted for 62% of the procedures performed on women and 79% of procedures performed on men in 2021. As part of the post-operative procedure, intranasal splints are used to promote hemostasis, structural support and minimize scar formation. Therefore, owing to the rising numbers of rhinoplasty surgery and the use of nasal splints for post-operative care, the market for nasal splints is forecasted to grow. The nasal splints market was limited by a shortage of skilled surgeons and other professionals in most developed and developing countries. Equipment fabrication and integration require specialized skillsets relating to nasal surgeries, and electronics and software. According to a survey conducted by the International Society of Aesthetic Plastic Surgery (ISAPS), in the Middle Eastern countries such as Iran, there were only 238 surgeons to perform 37,423 nose jobs. The specialized skillsets relating to nasal surgeries are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled surgeons and other professionals is a significant deterrent to the growth of the market. Nasal splints made from biodegradable materials are gaining popularity in the industry, as they do not require surgical removal after implantation. The biodegradable materials in nasal splints include plant-based and bioresorbable materials. They help in controlling bleeding after surgery or nasal trauma, eliminating the need for painful nasal packing removal for patients, and act as an adjunct to aid in the natural healing process. For instance, Smith & Nephew offers a dissolvable nasal splint Nasastent composed of plant-based carboxymethyl cellulose that helps to support the soft nasal tissue and provides pressure to prevent bleeding. This implant eventually converts into a hydro colloidal gel after absorbing nasal fluid and drains from the patient naturally. Some of the other companies offering biodegradable nasal splints are Hemostasis LLC., Medtronic and others. As per the US FDA, nasal splints are classified as Class I medical devices that are exempted from premarket notification. However, nasal splint manufacturers must register their establishment and list the generic category or classification name. Major players in the nasal splints market are Boston Medical Products Inc., Innovia Medical LLC., Medtronic PLC., Olympus Corporation, Smith & Nephew, DTR Medical, Mentor Worldwide LLC., Network Medical Products, Summit Medical Group, and Surgiform Technologies LLC. Asia-Pacific was the largest region in global nasal splints market in 2022. North America was the second-largest region in the nasal splints market. The regions covered in the global nasal splints market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nasal splints market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The nasal splints market consists of sales of instruments such as malleable nasal splints, airway nasal splints, and bivalve nasal splints. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nasal splints market is segmented - 1)By Type: Malleable Nasal Splints, Airway Nasal Splints, Bivalve Nasal Splints, 2) By End User: Hospitals & Clinics, Homecare, Research Centers, Other End Users 3) By Application: Plastic Surgery, Rhinological operations, ENT-Surgery, Other Applications 4) By Route of Administration: Intranasal Segment, Extranasal Segment

Anesthesia medication is used to cause a temporary loss of sensation in patients. Anesthesia disposables are the single-use, portable, and easy-to-use devices that prevent the risk of infections in patients. The main products of anesthesia disposables are anesthesia breathing circuits, endotracheal tubes, anesthesia gas masks, and laryngeal mask airway. Laryngeal mask airways (LMA) are supraglottic devices that are used as a temporary method to maintain an open airway during the administration of anesthesia or as an immediate life-saving measure in a patient with a difficult or failed airway. The patient groups are neonatal, adult, and pediatric. The various end-users are hospitals, clinics, home care settings, and other end users. The anesthesia disposables market research report is one of a series of new reports from The Business Research Company that provides anesthesia disposables market statistics, including anesthesia disposables industry global market size, regional shares, competitors with a anesthesia disposables market share, detailed anesthesia disposables market segments, market trends and opportunities, and any further data you may need to thrive in the anesthesia disposables industry. This anesthesia disposables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anesthesia disposables market size will grow from $1 billion in 2022 to $1.06 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The anesthesia disposables market size is expected to grow to $1.3 billion in 2027 at a CAGR of 5.2%. The increase in the aging population leads to increased surgeries driving the anesthesia disposable market. Increasing life expectancies paired with age-related comorbidities have resulted in the growth of the elderly population who undergo surgeries. The prevalence of cardiovascular disease, arthritis, thyroid disease, and emphysema is steadily increasing, which is proportionally increasing the number of surgeries coupled with the growing prevalence of diseases. These diseases are found mainly in elderly people, which is increasing the consumption of anesthesia disposables as they are widely used in surgical procedures and are driving the market in the forecast period. Lack of trained anesthesiologists is restraining the market. Anesthetist plays a very vital role in patient's care during and posts any surgery or operation. They acquire the ability to offer a premium level of care to their patients. As with the increase in the number of patients especially for surgery and operations across the globe, the demand for skilled and trained anesthetists also increases. To meet rising patient demand for anesthesia services, countries are facing a critical shortage of skilled and trained anesthetists. For example, the Centre for Workforce Intelligence, a unit of UK NHS staffing agency Health Education England stated that according to their study, the demand for anesthetic services would grow by 25% by 2033, and would require the number of anesthetists to grow by 300 a year. As reported in a study conducted by the American Association of Medical Colleges (AAMC), a shortfall of 33,800 to 72,700 physicians across the specialties is expected by 2030. Thus there is a significant gap in the requirement of trained anesthesiologists across the country which is likely to hinder the growth of the anesthesia disposables market. The demand for cuffed endotracheal tubes (ETTs) in pediatrics is growing as compared to uncuffed ETTs. During pediatric anesthesia, general endotracheal intubation is commonly performed for airway management and positive pressure ventilation. Traditionally, uncuffed endotracheal tubes (ETTs) are recommended for children up to eight years old. But the major disadvantages of the uncuffed ETTs such as an increase in air leakage around the tube, make it difficult to ensure that the child is breathing adequate amounts of oxygen. In addition, the measurement of tidal volume is also compromised. Uncuffed ETTs also allow waste anesthetic gases to escape, contributing significantly to operating room contamination and rendering the anesthetic procedure more expensive. Therefore, the trend is towards increasing the usage of cuffed ETTs for pediatric procedures. According to the American Association of Nurse Anesthetists, facilities should select disposables registered with the U.S. Environmental Protection Agency (EPA) and follow manufacturer recommendations regarding use, exposure time, and disposal. Also, they should discard disposable single-use devices in a biohazardous bag/container (e.g., breathing circuits, airway devices, orogastric tubes) immediately after use. Major players in the anesthesia disposables market are Ambu A/S, Medline Industries Inc., Smiths Medical, Teleflex Inc., Vyaire Medical Inc., Armstrong Medical Ltd., Hamilton Medical AG, Intersurgical Ltd., Medtronic PLC., and Mercury Medical. Asia-Pacific was the largest region in the global anesthesia disposables market in 2022. Western Europe was the second-largest region in the anesthesia disposables market. The regions covered in the global anesthesia disposables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anesthesia disposables market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The anesthesia disposables market consists of sales of instruments such as anesthesia circuits, anesthesia masks, sample lines, filters/Heat & Moisture Exchangers (HMEs), breathing bag, endotracheal tubes, and laryngeal masks. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anesthesia disposables market is segmented - 1) By Product: Anesthesia Breathing Circuits, Endotracheal Tubes, Anesthesia Gas Masks, Laryngeal Mask Airway 2) By End Users: Hospitals, Clinics, Home Care Settings, Other End users 3) By Patient Group: Neonatal, Adult, Pediatric

Respiratory devices and equipment (therapeutic) are used to treat patients with acute or chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, sleep disorders, etc. The main products of the respiratory devices and equipment (therapeutic) market are nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, and gas analyzers. A nebulizer is a small machine that turns liquid medicine into a mist, sits with the machine, and breathes in by a connected mouthpiece. The various technologies involved in the respiratory devices and equipment are HEPA filter, electrostatic filtration, microsphere separation, hollow fiber filtration, and others. The market covered in this report is segmented by end-users into home care settings and hospitals. The respiratory devices and equipment (therapeutic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (therapeutic) market statistics, including respiratory devices and equipment (therapeutic) industry global market size, regional shares, competitors with a respiratory devices and equipment (therapeutic) market share, detailed respiratory devices and equipment (therapeutic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (therapeutic) industry. This respiratory devices and equipment (therapeutic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global respiratory devices and equipment (therapeutic) market size will grow from $18.03 billion in 2022 to $19.90 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global respiratory devices and equipment (therapeutic) market size is expected to grow to $29.55 billion in 2027 at a CAGR of 10.4%. The market for respiratory devices and equipment is expected to expand rapidly. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of respiratory monitoring devices, in turn contributing to the growth of this market. Currently, there is a huge demand for respiratory devices including ventilators, especially in developing countries. Companies across the globe are focusing on increasing the availability of ventilators, nebulizers, and other respiratory support devices for patients. The rising prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disorder (COPD) and sleep apnea contributed to the growth of the therapeutic respiratory devices and equipment market. According to World Health Organization, one million people die due to chronic obstructive pulmonary diseases caused by smoking among the 4.9 million people who die due to tobacco consumption and 65 million people suffer from moderate to severe COPD. As per its estimates, COPD is predicted to be the third leading cause of death worldwide and potentially fatal respiratory diseases. Tuberculosis, COPD, and lung cancer will account for about one in five deaths worldwide by 2030. According to National Health Interview Survey by the Centers for Disease Control and Prevention (CDC), the number of adults with diagnosed chronic bronchitis in the USA was 9.0 million. In the USA, it is estimated that 22 million Americans suffer from sleep apnea, with 80% of the cases of moderate and severe obstructive sleep apnea undiagnosed. According to a research study published on American Journal of Respiratory and Critical Care Medicine, in 2021, global prevalence of obstructive sleep apnea was found to be around 20% globally. The increased prevalence of COPD and sleep apnea in the geriatric population is driving the market for therapeutic respiratory devices. Lack of awareness regarding the usage of respiratory devices has always been a major challenge in the therapeutic respiratory device market. Outcomes for patients with chronic respiratory diseases remain poor despite the development of novel therapies. An International Survey conducted on Noninvasive Ventilation Use for Acute Respiratory Failure in General Non-Monitored Wards in 51 countries from 5 continents revealed that 44% of the GPs and physicians reported that they had never performed spirometry to make a diagnosis of COPD and the NIV application in general wards was reported by only 66% of respondents. Limited training and human resources were the most common reasons for not using NIV in general wards. The lack of awareness on the use of respiration devices is negatively affecting the respiratory devices and therapeutics market. The companies in the respiratory devices and equipment therapeutic market are increasingly using AI to develop respiratory devices to treat Asthma and COPD. Artificial intelligence supports the development of innovative sensors-equipped inhalers which help patients to track their dosage intake. These sensors are durable and consume less power and help caution the patients by noting the differences or fluctuations in respiration. These are used for both add-on and embedded inhalers. These inhalers with sensors can track data automatically and can alert both the doctors and patients about the health condition of the patients. Also, the companies in developing devices such as AI aided imaging systems and AI aided platforms that will act as voice biomarkers. For instance, in March 2022, Respira Labs, a US-based respiratory technology company, launched AI-powered wearable lung monitor ‘Sylvee’. The new product uses acoustic resonance to assess the lung function and detect any variations in the lung function. In March 2020, Masimo, a global leader in noninvasive monitoring technologies acquired NantHealth, Inc's connected care business for an undisclosed amount. NantHealth is a provider a tablet-optimized application that sits on top of our DCX platform to provide clinicians more convenient and ubiquitous access to capture a wide array of patient vitals such as respiratory rate, blood pressure, and heart rate in addition to performing patient assessments. This move of Masimo will leverage its capabilities with NantHealth’s solutions that can enable a more efficient patient rounding and assessment workflow by providing a near real-time stream of data from the patient's bedside unlike periodic sampling typically entered into an EHR hours later. Major players in the respiratory devices and equipment (therapeutic) market are Hamilton Medical AG, Koninklijke Philips N.V, Smiths Medica, Ge Healthcare, Philips Health Care, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, Resmed, and Dragerwerk AG. Asia-Pacific was the largest region in the respiratory devices and equipment (therapeutic) market in 2022. Western Europe was the second-largest region in the global respiratory devices and equipment (therapeutic) market. The regions covered in the global respiratory devices and equipment (therapeutic) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (therapeutic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory devices and equipment (therapeutic) market consist of sales of instruments such as nebulizers, oxygen concentrators, positive airway pressure devices, ventilators, inhalers, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global respiratory devices and equipment (therapeutic) market is segmented - 1) By Product: Nebulizers, Humidifiers, Oxygen Concentrators, Positive Airway Pressure Devices, Ventilators, Capnographs, Gas Analyzers 2) By End-User: Homecare settings, Hospitals 3) By Technology: HEPA Filter, Electrostatic Filtration, Microsphere Separation, Hollow Fiber Filtration, Other Technologies

Positive airway pressure devices are devices that pump air under pressure into the lungs. These devices are used to treat obstructive sleep apnea (OSA). The main types of positive airway pressure devices are continuous positive airway pressure (CPAP), auto-titrating positive airway pressure (APAP), and bilevel positive airway pressure (BiPAP). Continuous positive airway pressure devices use mild air pressure to keep the airways open and are used for the treatment of patients who have breathing problems during sleep. Auto-titrating positive airway pressure devices are used for the determination of an optimal fixed level of continuous positive airway pressure (CPAP) for long-term treatment with a conventional CPAP device and help in maintaining the least amount of pressure integrity of the airway. Bilevel positive airway pressure devices are used to push air through the lungs using two different machines, one for higher pressure when breathing in and the other with a lower pressure when breathing out. These devices are used for the treatment of sleep apnea, COPD, and other disorders. The user of positive airway pressure devices includes hospitals & sleep labs, home care settings, and others. The positive airway pressure devices market research report is one of a series of new reports from The Business Research Company that provides positive airway pressure devices market statistics, including positive airway pressure devices industry global market size, regional shares, competitors with a positive airway pressure devices market share, detailed positive airway pressure devices market segments, market trends and opportunities, and any further data you may need to thrive in the positive airway pressure devices industry. This positive airway pressure devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global positive airway pressure devices market size grew from $3.51 billion in 2022 to $3.83 billion in 2023 at a compound annual growth rate (CAGR) of 9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The positive airway pressure devices market size is expected to grow to $5.53 billion in 2027 at a CAGR of 9.6%. The increase in geriatric population is expected to contribute to the growth of the positive airway pressure (PAP) devices market in the forecast period. The geriatric population is more prone to sleep apnea diseases. The higher prevalence of obstructive sleep apnea (OSA) is related to the decrease in the size of the upper airway lumen because of increasing age. According to the UN World Ageing Population 2020 report, there were 727 million persons aged 65 years or over in 2020, accounting for 9.3% of the total population. It is estimated that the ageing population will reach over 1.5 billion, accounting for 16% in 2050. Thus, the rising geriatric population as the existence of apnea is more prevalent in the geriatric population, and this is likely to drive the market. The launch of innovative and technologically advanced products by the industry players is gaining popularity in the positive airway devices market.  For instance, in September 2020, keeping, a start-up company developing disruptive solutions for the medication of obstructive sleep apnea (OSA), has designed and developed keePAP. keePAP will help in maintaining airway pressure to keep the upper airway open; this will support the user's respiratory system to deliver just the amount of PAP needed intermittently and with minimal airflow. Thus, companies operating in the market are continuously focusing on introducing new technologies to survive in the positive airway pressure devices market. The limited affordability of positive airway pressure devices due to the high cost associated with positive airway pressure machines proved to be a restraint for the positive airway pressure devices market in the forecast period. The prices of these machines depend on the type of functions offered by the machines. For instance, according to the SleepFoundation.org article published in January 2021, the average price of non-insured continuous positive airway pressure (CPAP) devices can range anywhere from $250 to $1,000, whereas bilevel positive airway pressure (BiPAP) devices can cost around $1,000 to $6,000, due to their complexity. High prices of positive airway pressure devices hindered the growth of the market during the period. Portable positive airway pressure devices are a growing trend in the positive airway pressure devices market. Positive airway pressure device manufacturing companies are increasingly investing in portable and easy-to-use continuous positive airway pressure devices to provide effective and fast breathing support. For instance, in September 2022, Transcend Inc., a US-based company specialising in portable CPAP technology, launched Transcend Micro. Transcend Micro is a portable continuous positive airway pressure (CPAP) device that is both the smallest and lightest. Transcend Micro, which weighs less than a pound and is less than four inches long, is made to make it easier for those who experience obstructive sleep apnea to continue their sleep apnea therapy at home or while travelling.  In March 2022, Owens & Minor, Inc., a US-based healthcare solutions company, acquired Apria, Inc for $1.6 billion. The acquisition created the most comprehensive selections of ancillary goods to serve people with both chronic and non-chronic ailments and an extensive paradigm for product supply and distribution. Apria, Inc is a US-based company providing integrated home healthcare equipment and related services, including continuous positive airway pressure.  Major players in the positive airway pressure devices market are ResMed Inc., Koninklijke Philips N.V., 3B Medical Inc., Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, Somnetics International Inc., Heyer Medical, Genstar Technologies, BMC Medical, Apex Medical, Armstrong Medical, Curative Medical, Compumedics Limited, CareFusion Corporation (Becton Dickinson and Company), Mercury Medical (Mercury Enterprises Inc.), and Khayat Medical. North America was the largest region in the positive airway pressure devices market in 2022. Asia-Pacific is predicted to record the fastest growth over the forecast period. The regions covered in the positive airway pressure devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the positive airway pressure devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The positive airway pressure devices market consists of sales of adjustable positive airway pressure and variable positive airway pressure devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global positive airway pressure devices market is segmented - 1) Product Type: Continuous Positive Airway Pressure (CPAP), Auto-titrating Positive Airway Pressure (APAP), BiLevel Positive Airway Pressure (BiPAP) 2) By Application: Sleep Apnea, COPD, Other Applications 3) By End-user: Hospitals & Sleep Labs, Home Care Settings, Other End-users

Resuscitation devices are used in crises to assist in the process of reviving the patient's breath or inducing spontaneous breathing in patients who are unconscious or appear to be dead by inflating the lungs with positive pressure, which maintains the patient oxygenated. Resuscitation devices are typically disposable, latex-free, and intended for single-patient use. The main types of resuscitation devices are airway management devices, external defibrillators, convective warming blankets, and other resuscitation devices. Airway management devices include a set of equipment and medical procedures performed to prevent and relieve airway obstruction. The devices assure the gas exchange between a patient's lungs and the atmosphere is unhindered. They are used by adult patients and paediatric patients and implemented in various sectors such as hospitals, diagnostic centers, ambulatory surgical centers, and others. The resuscitation devices market research report is one of a series of new reports from The Business Research Company that provides resuscitation devices market statistics, including resuscitation devices industry global market size, regional shares, competitors with a resuscitation devices market share, detailed resuscitation devices market segments, market trends and opportunities, and any further data you may need to thrive in the resuscitation devices industry. This resuscitation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global resuscitation devices market size grew from $8.24 billion in 2022 to $8.76 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The resuscitation devices market size is expected to grow to $11.1 billion in 2027 at a CAGR of 6.1%. The increase in incidences of cardiac and respiratory diseases is expected to propel the growth of the resuscitation devices market in the coming years. The main reasons for the rise in cardiac and respiratory diseases are aging, smoking, pollution, an unhealthy diet, physical inactivity, tobacco use, and harmful use of alcohol. Further, behavioural risk factors such as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity can also cause a high risk of cardiovascular diseases.  Resuscitation devices help to restore blood circulation and breathing of a person suffering from cardiac and respiratory diseases in an emergency. For instance, according to the American College of Cardiology, a US-based non-profit medical association, all four CV risk factors are anticipated to rise in prevalence among the general U.S. population between 2025 and 2060, with diabetes showing the largest percentage increase of 39.3%, followed by dyslipidemia, hypertension, and obesity. The most significant anticipated rate increases were heart failure at 33.4% and stroke at 33.8%. Therefore, the rising prevalence of cardiac and respiratory diseases drives the growth of the resuscitation devices market. The development of novel resuscitation devices is a key trend gaining popularity in the resuscitation devices market. Novel resuscitation devices can help improve patients’ survival after prolonged cardiac arrest (heart attack) and reduce neurologic injury. Major players operating in the resuscitation devices market are indulging in the development of novel resuscitation devices to meet customer demand and strengthen their position. For instance, in June 2020, ZOLL Medical Corporation, a US-based company that manufactures medical devices and related software solutions, launched the ZOLL AED 3 defibrillator. ZOLL AED 3 makes delivery of CPR that adheres to guidelines easier with the Real CPR Help technology and integrated, real-time feedback. The enhanced Real CPR Help includes a full-colour display with realistic rescue visuals, a CPR cycle timer, and a sizable colour bar gauge that displays CPR compression depth. A soothing voice instructs rescuers to halt when the cardiac analysis is finished. It also warns them if a shock is necessary or if CPR should be restarted. In September 2021, Cardio Partners, Inc., a US-based company specialising in emergency preparedness solutions, acquired Allied 100, LLC, for an undisclosed amount. Through this acquisition, Cardio Partners and Allied 100 offer professional and lay first responder markets with enhanced sudden cardiac arrest (SCA) solutions, training, and services. Allied 100 is a US-based company specialising in automated external defibrillators and related accessories. Major players in the resuscitation devices market are Koninklijke Philips N.V., Medtronic plc, Physio-Control, Drägerwerk AG, Ambu A/S, 3M, GE Healthcare, ZOLL Medical Corporation, Nihon Kohden Corporation, Cardinal Health, Mindray Medical International Limited, Teleflex, Intersurgical, Salter Labs Inc., Smiths Medical, Vyaire Medical, RAPP Australia, and Neotech Medical Systems Pvt. Ltd. North America was the largest region in the resuscitation devices market in 2022. Europe was the second-largest region in the resuscitation devices market. The regions covered in the resuscitation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the resuscitation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The resuscitation devices market consists of sales of ICU ventilators, portable ventilators, endotracheal tubes, resuscitators, tracheostomy tubes, external defibrillators, convective warming blankets, and other resuscitation devices.  Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global resuscitation devices market is segmented - 1) By Product: Airway Management Devices, External Defibrillators, Convective Warming Blankets, Other Products 2) By Patient Type: Adult Patients, Pediatric Patients 3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End-users